share_log

Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.5

Needham Maintains Buy on Lucid Diagnostics, Lowers Price Target to $2.5

Needham维持对Lucid Diagnostics的买入,将目标价下调至2.5美元
Benzinga ·  2023/11/14 13:43

Needham analyst Mike Matson maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and lowers the price target from $2.8 to $2.5.

Needham分析师迈克·马特森维持Lucid Diagnostics(纳斯达克股票代码:LUCD)的买入,并将目标股价从2.8美元下调至2.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发